Thromb Haemost 2019; 119(12): 1933-1946
DOI: 10.1055/s-0039-1696713
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear

Wenjing Cao
1   Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
,
Mohammad S. Abdelgawwad
1   Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
,
Jingzhi Li
1   Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
,
1   Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, United States
› Author Affiliations
Funding The study was in part supported by grants from R01HL126724 and R01HL115187 (to X.L.Z.).
Further Information

Publication History

03 February 2019

19 July 2019

Publication Date:
07 September 2019 (online)

Abstract

Background Proteolytic cleavage of von Willebrand factor (VWF) by a plasma a disintegrin and metalloproteinase with a thrombospondin type 1 motifs, member 13 (ADAMTS13) is regulated by shear stress and binding of coagulation factor VIII, platelets or platelet glycoprotein 1b, and ristocetin to VWF.

Objective Current study aims to identify novel VWF binding partners that may modulate VWF functions under physiological conditions.

Methods A deoxyribonucleic acid aptamer-based affinity purification of VWF, followed by tandem mass spectrometry, functional, and binding assays was employed.

Results Apolipoprotein B100/low-density lipoprotein (apoB100/LDL) was identified as a novel VWF-binding partner. Purified apoB100/LDL was able to accelerate the proteolytic cleavage of VWF by ADAMTS13 under shear in a concentration-dependent manner. This rate-enhancing activity was dramatically reduced when apoB100/LDL was oxidized. More interestingly, the oxidized apoB100/LDL appeared to compete with native apoB100/LDL for its enhancing activity on VWF proteolysis under shear. As a control, a purified apoA1/high-density lipoprotein (apoA1/HDL) or apoB48 exhibited a minimal or no activity enhancing VWF proteolysis by ADAMTS13 under the same conditions. Both VWF and ADAMTS13 were able to bind native or oxidized apoB100/LDL with high affinities. No binding interaction was detected between VWF (or ADAMTS13) and apoA1/HDL (or apoB48). Moreover, apoB100/LDL but not its oxidized products inhibited the adhesion of platelets to ultra large VWF released from endothelial cells under flow. Finally, significantly reduced ratios of high to low molecular weight of VWF multimers with increased levels of plasma VWF antigen were detected in LDLR−/− mice fed with high cholesterol diet.

Conclusion These results indicate that apoB100/LDL may be a novel physiological regulator for ADAMTS13-VWF functions.

Authors' Contributions

W.C., M.S.A., J.L., and X.L.Z. designed and performed experiments, analyzed the data, interpreted results, and wrote the manuscript.


 
  • References

  • 1 Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 2015; 66: 211-225
  • 2 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3 (08) 1702-1709
  • 3 Sadler JE, Mancuso DJ, Randi AM, Tuley EA, Westfield LA. Molecular biology of von Willebrand factor. Ann N Y Acad Sci 1991; 614: 114-124
  • 4 Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010; 91 (01) 20-29
  • 5 Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4 (06) 1396-1404
  • 6 Liu L, Choi H, Bernardo A. , et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3 (11) 2536-2544
  • 7 South K, Freitas MO, Lane DA. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity. J Thromb Haemost 2016; 14 (10) 2011-2022
  • 8 Muia J, Zhu J, Gupta G. , et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111 (52) 18584-18589
  • 9 Dong JF, Moake JL, Nolasco L. , et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100 (12) 4033-4039
  • 10 Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol 2011; 31 (10) 2261-2269
  • 11 Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110 (06) 1887-1894
  • 12 Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 2008; 105 (21) 7416-7421
  • 13 Skipwith CG, Cao W, Zheng XL. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285 (37) 28596-28603
  • 14 Yang CY, Gu ZW, Weng SA. , et al. Structure of apolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis 1989; 9 (01) 96-108
  • 15 Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42 (09) 1346-1367
  • 16 Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88 (06) 1785-1792
  • 17 Edelstein C, Nakajima K, Pfaffinger D, Scanu AM. Oxidative events cause degradation of apoB-100 but not of apo[a] and facilitate enzymatic cleavage of both proteins. J Lipid Res 2001; 42 (10) 1664-1670
  • 18 Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990; 343 (6258): 531-535
  • 19 Huang RH, Fremont DH, Diener JL, Schaub RG, Sadler JE. A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. Structure 2009; 17 (11) 1476-1484
  • 20 McDaniel JK, Abdelgawwad MS, Hargett A. , et al. Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols. J Thromb Haemost 2019; 17 (04) 596-606
  • 21 Laje P, Shang D, Cao W. , et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood 2009; 113 (10) 2172-2180
  • 22 Kumar M, Cao W, McDaniel JK. , et al. Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage. Thromb Haemost 2017; 117 (04) 691-699
  • 23 Oney S, Nimjee SM, Layzer J. , et al. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 2007; 17 (03) 265-274
  • 24 Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 1990; 64 (02) 326-332
  • 25 Fong LG, Parthasarathy S, Witztum JL, Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 1987; 28 (12) 1466-1477
  • 26 Zhang L, Lawson HL, Harish VC, Huff JD, Knovich MA, Owen J. Creation of a recombinant peptide substrate for fluorescence resonance energy transfer-based protease assays. Anal Biochem 2006; 358 (02) 298-300
  • 27 Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI. The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J 1986; 5 (13) 3495-3507
  • 28 Chung DW, Chen J, Ling M. , et al. High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood 2016; 127 (05) 637-645
  • 29 Kowala MC, Recce R, Beyer S, Gu C, Valentine M. Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000; 149 (02) 323-330
  • 30 Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92 (02) 883-893
  • 31 Raife TJ, Cao W, Atkinson BS. , et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114 (08) 1666-1674
  • 32 Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-277
  • 33 Fuchigami S, Kaikita K, Soejima K. , et al. Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina. Thromb Res 2008; 122 (05) 618-623
  • 34 Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006; 4 (11) 2490-2493
  • 35 Andersson HM, Siegerink B, Luken BM. , et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 2012; 119 (06) 1555-1560
  • 36 Sonneveld MA, de Maat MP, Portegies ML. , et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood 2015; 126 (25) 2739-2746
  • 37 Zhao BQ, Chauhan AK, Canault M. , et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114 (15) 3329-3334
  • 38 Khan MM, Motto DG, Lentz SR, Chauhan AK. ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. J Thromb Haemost 2012; 10 (08) 1665-1671
  • 39 Hassenpflug WA, Budde U, Obser T. , et al. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006; 107 (06) 2339-2345
  • 40 Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11 (Suppl. 01) 11-23
  • 41 Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106 (23) 9226-9231
  • 42 Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324 (5932): 1330-1334
  • 43 Verbree-Willemsen L, Zhang YN, Gijsberts CM. , et al; METEOR Study Group. LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. Int J Cardiol 2018; 271: 247-253
  • 44 Ahotupa M. Oxidized lipoprotein lipids and atherosclerosis. Free Radic Res 2017; 51 (04) 439-447
  • 45 Zouaoui Boudjeltia K, Moguilevsky N, Legssyer I. , et al. Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochem Biophys Res Commun 2004; 325 (02) 434-438
  • 46 Bertoia ML, Pai JK, Lee JH. , et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol 2013; 61 (21) 2169-2179
  • 47 Ryglewicz D, Rodo M, Roszczynko M. , et al. Dynamics of LDL oxidation in ischemic stroke patients. Acta Neurol Scand 2002; 105 (03) 185-188
  • 48 Tsimikas S, Kiechl S, Willeit J. , et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006; 47 (11) 2219-2228
  • 49 Staprãns I, Rapp JH, Pan XM, Kim KY, Feingold KR. Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. Arterioscler Thromb 1994; 14 (12) 1900-1905
  • 50 Silverstein RL. Disabling the platelet's brakes to promote thrombosis. Blood 2015; 125 (17) 2591-2593